• 1. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Recent Advances in the Study of 4-(1,3,5-Trimethyl-1H-Pyrazol-4-yl)Butanoic Acid (CAS: 1708251-35-7)

In recent years, the compound 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid (CAS: 1708251-35-7) has garnered significant attention in the field of chemical biology and medicinal chemistry. This molecule, characterized by its unique pyrazole core and butanoic acid side chain, has shown promising potential in various therapeutic applications. The latest research has focused on elucidating its pharmacological properties, synthetic pathways, and potential as a scaffold for drug development.

A recent study published in the Journal of Medicinal Chemistry explored the anti-inflammatory properties of 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid. The research demonstrated that this compound exhibits potent inhibitory effects on key inflammatory mediators, such as cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α). These findings suggest its potential as a lead compound for developing novel anti-inflammatory agents with reduced side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Another significant advancement comes from a 2023 study in Bioorganic & Medicinal Chemistry Letters, which investigated the compound's role as a building block for more complex molecules. Researchers successfully utilized 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid as a versatile intermediate in the synthesis of various heterocyclic compounds with enhanced biological activity. The study highlighted the molecule's structural flexibility and its ability to serve as a core structure for designing targeted therapies.

From a synthetic chemistry perspective, recent work has focused on optimizing the production of 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid. A team at the University of Cambridge developed a more efficient and scalable synthetic route that reduces production costs while maintaining high purity. This advancement is particularly important for potential industrial-scale applications and further pharmacological testing.

In the field of drug discovery, computational studies have revealed interesting insights into the molecular interactions of 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid with various biological targets. Molecular docking simulations suggest that the compound may have affinity for multiple protein targets involved in metabolic disorders, opening new avenues for its application in diabetes and obesity research.

Despite these promising developments, challenges remain in fully characterizing the pharmacokinetic profile and safety of 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid. Current research efforts are focused on addressing these gaps through comprehensive in vivo studies and structure-activity relationship (SAR) analyses. The compound's future in drug development will largely depend on these ongoing investigations.

In conclusion, 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)butanoic acid (CAS: 1708251-35-7) represents an exciting area of research in chemical biology and medicinal chemistry. Its diverse biological activities, synthetic versatility, and potential therapeutic applications make it a compound worth watching in the coming years. As research progresses, we anticipate more concrete applications emerging for this promising molecule.

• 1258651-72-7(3-(3,5-diethyl-1-methyl-1H-pyrazol-4-yl)propanoic acid)
• 1007464-61-0(2-methyl-3-(trimethyl-1H-pyrazol-4-yl)propanoic acid)
• 2229006-83-9(2-methyl-4-(trimethyl-1H-pyrazol-4-yl)butanoic acid)
• 2228661-12-7(3-methyl-3-(trimethyl-1H-pyrazol-4-yl)butanoic acid)
• 956352-96-8(3-(1,3,5-Trimethyl-1H-pyrazol-4-yl)propanoic Acid)
• 1269087-62-8(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propanoic acid hydrochloride)
• 2228183-16-0(2,2-dimethyl-3-(trimethyl-1H-pyrazol-4-yl)propanoic acid)
• 2228564-11-0(1-(trimethyl-1H-pyrazol-4-yl)methylcyclopropane-1-carboxylic acid)
• 1006446-62-3(3-(1,5-dimethyl-1H-pyrazol-4-yl)propanoic acid)
• 1006490-35-2(3-(1,3-Dimethyl-1H-pyrazol-4-yl)propanoic Acid)